| Income Statement | 2026-06-30 | 2026-03-31 | ||
|---|---|---|---|---|
| Collaboration revenue | 0 | 0 | ||
| Research and development | 36,226,000 | 32,321,000 | ||
| General and administrative | 10,511,000 | 7,350,000 | ||
| Change in fair value of contingent consideration | 8,733,000 | 109,000 | ||
| Total operating expenses | 55,470,000 | 39,780,000 | ||
| Operating loss | -55,470,000 | -39,780,000 | ||
| Interest income | 2,832,000 | 1,708,000 | ||
| Interest expense | 20,000 | 10,000 | ||
| Other expense, net | -138,000 | -117,000 | ||
| Total other income, net | 2,674,000 | 1,581,000 | ||
| Loss before income taxes | -52,796,000 | -38,199,000 | ||
| Income tax provision | -8,000 | 63,000 | ||
| Net loss | -52,788,000 | -38,262,000 | ||
| Foreign currency translation adjustment | 113,000 | -306,000 | ||
| Unrealized gain (loss) on marketable securities, net of tax | -471,000 | -86,000 | ||
| Total other comprehensive (loss) income | -358,000 | -392,000 | ||
| Comprehensive loss | -53,146,000 | -38,654,000 | ||
| Basic EPS | -1.74 | -6.77 | ||
| Diluted EPS | -1.74 | -6.77 | ||
| Basic Average Shares | 30,277,051 | 5,655,716 | ||
| Diluted Average Shares | 30,277,051 | 5,655,716 | ||
Odyssey Therapeutics, Inc. (ODTX)
Odyssey Therapeutics, Inc. (ODTX)